Microbleed prevalence and burden in anticoagulant-associated intracerebral bleed.

86%) over a 2‐year follow‐up period, although this did not reach statistical significance ( P = 0.071) due to the low number of events. 3 Similarly, in a secondary analysis of the NAVIGATE‐ESUS trial (Shoamanesh et al., oral presentation in International Stroke Conference 2019), the risk of ICH in the rivaroxaban‐allocated group was not affected by CMB presence compared to aspirin.

also in 111,027 other papers